skip to Main Content

Inhibition of PAK1 Suppresses Pancreatic Cancer by Stimulation of Anti-Tumour Immunity Through Down-Regulation of PD-L1

Newsfeed image, light gray text on dark gray background
Immunotherapies have not yielded significant clinical benefits for pancreatic ductal adenocarcinoma (PDA) because of the existence of an immunosuppressive tumour microenvironment (TME) characterised by a desmoplastic stroma containing infiltrated immune cells and activated pancreatic stellate cells (PSCs). {/subhead]

This study aims to investigate the involvement of PAK1 in anti-tumour immunity. Read more . . .  


Back To Top